On June 7, 2010, Ruby Acquisition, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc.,
a wholly-owned subsidiary of Astellas Pharma Inc., completed its Subsequent Tender Offer for
OSI Pharmaceuticals, Inc. (OSIP) Common Shares. The merger was subsequently consummated
on June 8, 2010. As a result, each existing OSIP Common Share will be converted into the right to receive $57.50 net cash per share.
This action will be coordinated with the Options Clearing Corporation.
Register for regular updates here and manage your email preferences.